Insulin Glargine Market Research Repo...
Home  »  Community News  »  Insulin Glargine Mar...
Insulin Glargine Market Research Reports With 2019 Global and China Forecasts as well as Comprehensive Patent Search Info
Pharma News

PR Newswire

DALLAS, June 3, 2015 /PRNewswire/ —

Global and Chinese Insulin Glargine Industry, 2009-2019 Market Research Report provides key statistics on the market status of the insulin glargine manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

The complete insulin glargine market report spread across 150 pages, talking about 8 companies and supported with 98 tables and figures is now available at .

This is a professional and in-depth study on the current state of the global insulin glargine market with a focus on the Chinese region. The research provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2009-2014 insulin glargine market market shares for each company. Through the statistical analysis, the report depicts the global and Chinese total market of Insulin Glargine industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.

The total insulin glargine market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates 2014-2019 market development trends of Insulin Glargine industry. Analysis of upstream raw materials, downstream demand, and current insulin glargine market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Insulin Glargine market before evaluating its feasibility. Overall, the report provides an in-depth insight of 2009-2019 global and Chinese Insulin Glargine market covering all important parameters.

2019 forecasts are provided for Global and Chinese Capacity, Production, and Production Value of Insulin Glargine, Cost and Profit Estimation, Market Share of Insulin Glargine, Supply and Consumption as well as Chinese Import and Export of Insulin Glargine in this market research report available for purchase at .

In China, the third generation of insulin is still in promotion period. Since its price is relatively high, it is mainly used in big cities. The second generation and the third generation of insulin will take the shape of stagger competition according to another research report titled Investigation Report on China Insulin Glargine Market, 2010-2019. According to a survey on some sample hospitals in China, the CAGR of insulin glargine in sample hospitals in China has exceeded 60% during the period of 2014-2015. Currently, the Chinese market is dominated mainly by Aventis Behring Gmbh (the trade name of insulin glargine is Lantus and the sales in 2014 exceeded USD 7 billion) and the generic drugs (the trade name of insulin glargine is Basalin) made by Gan & Lee Pharmaceutical. As the patent of Lantus expired in Feb. 2015, the global market structure is estimated to change in the next few years. On Sep.9, 2014, Eli Lilly and Company and Boehringer Ingelheim issued a joint statement that the insulin biosimilar insulin glargine owned by them has been approved to come into market by the EU. On the other hand, in Chinese market, some local enterprises are also hastening the development of Lantus’s generic drug.

With the improvement of living standards and the change of life styles in China, the incidence of diabetes has kept growing and the market size of diabetes drugs has expanded each year, exceeding CNY 20 billion in 2014 according to CRI’s research. Currently in China, the second generation of recombinant human insulin is the mainstream of market. Having reduced the defects of the second generation of insulin and effectively shortened the length of treatment, the third generation of insulin products is expected to substitute the second generation gradually. It is predicated that insulin glargine is a potential product of growth among all three generations of insulin products. This research provides reference price of insulin glargine in Chinese hospitals by Beijing Gan & Lee, Aventis Behring GmbH and Tonghua Dongbao. Major manufacturers ofChina insulin glargine market mentioned in this research include Gan & Lee Pharmaceuticals, Aventis Behring GmbH and Tonghua Dongbao Pharmaceutical Co., Ltd. Order a copy of Investigation Report on China Insulin Glargine Market, 2010-2019at .

A third report on Insulin Glargine – Comprehensive patent search covers information and data on insulin glargine for indications on Treatment of type 1 and type 2 diabetes mellitus for the control of hyperglycaemia and innovator: Sanofi-Aventis (Lantus, Lantus Optiset, Lantus Solostar, Optisulin, Optisulin Optiset, Optisulin Solostar). The In-depth search contains patents from territories that are individually verified and monitored for changes, including British, German, Spanish, French, US, Canadian, Australian, European, and PCT patents. This report helps identify patents covering molecule, formulation, process, use, combinations and more; grouped by patent family and assigned to development categories based on interpretation of key aspects of the patent claims and manual filtration of patents so only relevant information is visible. Read more at .

Explore more reports on the pharmaceuticals industry at .

About Us: is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:




G+ / Google Plus:



Ritesh Tiwari
TX, Dallas North – Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441

Leave a reply

You must be logged in to post a comment.